Skip to main content
. 2022 Mar 10;10:842813. doi: 10.3389/fcell.2022.842813

FIGURE 2.

FIGURE 2

ASO-210@IFNγ-sEVs inhibit the proliferation of PBMCs and T cells in vitro. (A) Representative confocal images of HaCaT and Jurkat cells when incubated with IFNγ-sEVs and ASO-210@IFNγ-sEVs. Scale bar: 10 μm. (B) Representative quantitative analysis of the effect of ASO-210 at time points on the mRNA expression of miRNA-210, STAT6, and LYN in Jurkat T cells (n = 3). (C) Representative Western blot of ASO-210 at time point on the expression of STAT6 and LYN in Jurkat T cells. (D,E) Flow cytometry analysis of the proliferation of PBMC or T cells in groups that received different treatments (IFNγ-sEVs, ASO-210, ASO-210&IFNγ-sEVs, and ASO-210@ IFNγ-sEVs) for 5 days. The PC group stands for PBMC or T cells cultured for the same days without drugs. NC group stands for PBMC or T cells on day 0. (F,G) The corresponding quantitative analysis of PBMC or T cells from different treatment groups (n = 3). Error bar, mean ± SD. n.s represents no significance, *p < 0.05, **p < 0.01, ***p < 0.001.